<br /> Manufacturers report bamlanivimab and etesevimab meets primary endpoint in BLAZE-1 trial for use in high risk COVID-19 patients | Medicines Awareness Service<br />

In this study of this neutralising antibody cocktail in mild to moderate COVID-19 in high risk patients, 2.1% of patients in given treatment required hospitalisation vs 7% for control. It also reduced viral load and sped up symptom resolution, although data has not been released.


Biospace Inc.

Source link